TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03132532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo PBT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02030756

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrating capsule
Description: patients will receive vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham non-vibrating capsule
Description: patients will receive sham non-vibrating capsule for 8 weeks of treatment \[1 every 3 days (+/- 1 day)\].
Study: NCT02525861

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA
Description: Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLASSIA
Description: Participants will receive weekly IV infusions of GLASSIA at 60 mg/kg BW active A1PI protein administered at a rate of 0.2 mL/kg/min for 25 weeks (25 planned infusions) via an IV administration.
Study: NCT04276766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crossover intervention
Description: Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Crossover intervention
Description: Drink consumption was followed by regular BP measurements and collection of saliva samples every 30 minutes for four hours. Microcirculatory measurements were then repeated and saliva and urine samples were collected again.~After the last measurement subjects were provided with a standardized meal with a very low nitrate intake to eat within 30minutes. Participant then left the research centre and they were asked to collect a saliva sample after two hours from the completion of the meal. This was immediately followed a dose of labelled nitrate (4mg in 100ml of distilled water) to drink within one minute. Subjects were then asked to collect six additional saliva samples until the next morning (four before going to bed and two in the morning), accompanied by measurements of resting BP.~Cross-over assessments were then repeated in the same order at Visit 3, followed a wash-out period of at least one week before entering the second arm of the study.
Study: NCT03042780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Description: The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
Study: NCT03579849

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary tomoscintigraphy
Description: The included patients will benefit from pulmonary tomoscintigraphy within 24 hours after the diagnosis of pulmonary embolism. Each tomoscintigraphy will be interpreted blindly by 3 nuclear physicians. Each of the 20 lung segments will be interpreted as normoperfused or hypoperfused.
Study: NCT02921568

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectral OCT/SLO
Description: Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
Study: NCT00900523

Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis

Intervention type: OTHER
Intervention: immunohistochemistry
Description: immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
Study: NCT02193360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFP104
Description: Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
Study: NCT01096888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced WIC Program
Description: Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
Study: NCT02925572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling exercises
Description: All measurements are performed before and after the training program (12 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling exercises
Description: All measurements are performed before and after the training program (12 weeks)
Study: NCT03531281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allo-HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goat Milk
Description: Given human lysozyme goat milk PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Palifermin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo FTBI

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Total-Body Irradiation
Description: Undergo FTBI
Study: NCT02649049

Intervention type: OTHER
Intervention: there is no intervention

Intervention type: OTHER
Intervention: there is no intervention
Study: NCT03186118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Description: Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Description: Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Description: Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
Description: Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
Study: NCT00633711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic (variable, automatically controlled) pressure CPAP
Description: CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.~Home nocturnal usage. Two-month treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed continuous positive airway pressure (CPAP)
Description: CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.~Home nocturnal usage. Two-month treatment.
Study: NCT02294682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
Study: NCT03133806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasept LAA Closure System
Description: The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
Study: NCT03422172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral CAB
Description: CAB tablet will be formulated as white to almost white, oval shaped, film coated 30 mg tablets, administered orally once daily. The CAB tablets will be packaged in bottles containing 30 tablets each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: CAB LA is a sterile white to slightly colored suspension containing 200 mg/mL of CAB as free acid for administration by IM injection in gluteus medius.
Study: NCT02595931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy Specimen
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study: NCT03217188

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: conventionally fractionated full dose re-irradiation
Description: re-irradiation \[60-70 Gy (RBE) in 2 Gy (RBE) fractions

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated palliative re-irradiation
Description: course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break \[+/- 2 weeks\], repeated up to 4 cycles).
Study: NCT00066742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00832117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
Study: NCT04699175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR021618
Description: Treatment group A:HR021618; high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR021618
Description: Treatment group B:HR021618; low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment group C: HR021618 blank preparation.
Study: NCT01647750

Intervention type: DRUG
Group type: OTHER
Intervention: Levothyroxine
Description: Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose

Intervention type: DRUG
Group type: OTHER
Intervention: Levothyroxine
Description: Participants in the standard dose of treatment will receive their usual dose of levothyroxine
Study: NCT02321826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants choice among 4 genres of music matched on music characteristics

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audiobook
Description: Participants choice among 4 types of audiobooks
Study: NCT00791336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: 1250 mg twice daily starting for approximately 6.5 weeks.
Study: NCT01996813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thigh-high compression stockings
Description: The intervention in this study are thigh-high compression stockings manufactured by Covidien.
Study: NCT01318954

Intervention type: BIOLOGICAL
Intervention: Allergen immunotherapy
Study: NCT02852161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnet assissted capsule endoscopy
Description: Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnet assissted capsule endoscopy
Description: Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
Study: NCT02215837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Chemotherapy
Description: Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ag-D-CIK
Description: 8×10\^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
Study: NCT01480453

Intervention type: DEVICE
Intervention: Trabecular Metal Humeral Stem
Description: Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
Study: NCT04559828

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental meal
Description: Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental meal
Description: Two dietary oils will be administrated as part of a single experimental meal, for the present is a postprandial phase study.
Study: NCT02599454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Into the vein Day 1 every 3 weeks for 6 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
Study: NCT03106181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent inject®
Description: Insertion of iStent inject®

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification and intraocular lens implant
Description: Conventional phacoemulsification cataract surgery and intraocular lens implant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens implant
Description: Conventional phacoemulsification cataract surgery and intraocular lens implant
Study: NCT00799279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation training, support, and telephone follow-up
Description: The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation intervention
Description: Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
Study: NCT02686021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole and Ibuprofen
Description: Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole and Placebo
Description: Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and Placebo
Description: Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Study: NCT00818389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT03399409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivation techniques

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-inflammatory Information
Description: Provision of information on anti-inflammatory products
Study: NCT01893229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium is used as a mood stabiliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Valproate is used as a mood stabiliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine is used as a mood stabiliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine is used as a mood stabiliser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine is used as a mood stabiliser.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone is used as a mood stabiliser
Study: NCT02041260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study: NCT02076217

Intervention type: DRUG
Intervention: Copper T-380 IUD

Intervention type: DRUG
Intervention: LNG IUD

Intervention type: DEVICE
Intervention: Contraceptive implant Nexplanon

Intervention type: DRUG
Intervention: Depo-Provera